Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis

Journal of the American Academy of Dermatology

Volumn 60, Issue 6, 2009, Pages 934-943

  Anderson, Lawrence ^a   Schmieder, George J ^b   Werschler, W Philip ^c   Tschen, Eduardo H ^d   Ling, Mark R ^e   Stough, Dow B ^f   Katsamas, Janelle ^g  

^a Dermatology Associates of Tyler   (United States)

^b Park Avenue Dermatology PA ^*  (United States)

^c Premier Clinical Research   (United States)

^d Academic Dermatology Associates   (United States)

^e MedaPhase Inc   (United States)

^f Burke Pharmaceutical Research Inc   (United States)

^g Peplin Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EUPHORBIA EXTRACT; INGENOL MEBUTATE; PEP 005; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BLISTER; CHILL; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; ERYTHEMA; FEMALE; FOLLOW UP; GEL; HEADACHE; HEMATOMA; HUMAN; IMPETIGO; INFLAMMATION; INFLUENZA; MALE; MUSCLE SPASM; NOSE CONGESTION; PARESTHESIA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISCOMFORT; SKIN IRRITATION; SKIN MANIFESTATION; SKIN NECROSIS; SKIN PAIN;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; DITERPENES; DOUBLE-BLIND METHOD; EUPHORBIA; GELS; HUMANS; KERATOSIS, ACTINIC; MIDDLE AGED; PLANT EXTRACTS; TREATMENT OUTCOME; VEHICLES;

EID: 65749118370     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.01.008     Document Type: Article

References (26)

1. Fuchs A., and Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 33 (2007) 1099-1101
2. Ackerman A.B., and Mones J.M. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 155 (2006) 9-22
3. Anwar J., Wrone D.A., Kimyai-Asadi A., and Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 22 (2004) 189-196
4. Cockerell C.J. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 42 (2000) 11-17
5. Lober B.A., and Lober C.W. Actinic keratosis is squamous cell carcinoma. South Med J 93 (2000) 650-655
6. Glogau R.G. The risk of progression to invasive disease. J Am Acad Dermatol 42 (2000) 23-24
7. Dinehart S.M., Nelson-Adesokan P., Cockerell C., Russell S., and Brown R. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 79 (1997) 920-923
8. Smith E.S., Feldman S.R., Fleischer Jr. A.B., Leshin B., and McMichael A. Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg 24 (1998) 981-985
9. Carlson J.A., Scott D., Wharton J., and Sell S. Incidental histopathologic patterns: possible evidence of 'field cancerization' surrounding skin tumors. Am J Dermatopathol 23 (2001) 494-496
10. Del Rosso J.Q. The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis 76 (2005) 241-248
11. Spencer J.M., Hazan C., Hsiung S.H., and Robins P. Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol 4 (2005) 296-301
12. Ogbourne S.M., Suhrbier A., Jones B., Cozzi S.J., Boyle G.M., Morris M., et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 64 (2004) 2833-2839
13. Challacombe J.M., Suhrbier A., Parsons P.G., Jones B., Hampson P., Kavanagh D., et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 177 (2006) 8123-8132
14. Hampson P., Wang K., and Lord J.M. PEP-005. Drugs Future 30 (2005) 1003-1005
15. Anderson L, Welburn P. Maximum tolerated dose of PEP005 Topical Gel for the treatment of actinic keratosis [ADA Poster P1503]. Paper presented at: American Academy of Dermatology 2007 Summer Meeting, August 1-5, 2007; New York, NY.
16. Siller G, Gebauer K, Welburn P. Treatment of actinic keratosis with PEP005 Topical Gel [AAD Poster P1900]. Paper presented at: American Academy of Dermatology 2006 Summer Meeting, July 26-30, 2006; San Diego, CA.
17. Jorizzo J., Dinehart S., Matheson R., Moore J.K., Ling M., Fox T.L., et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 57 (2007) 265-268
18. Lebwohl M., Dinehart S., Whiting D., Lee P.K., Tawfik N., Jorizzo J., et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50 (2004) 714-721
19. Korman N., Moy R., Ling M., Matheson R., Smith S., McKane S., et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 141 (2005) 467-473
20. Jorizzo J., Weiss J., Furst K., VandePol C., and Levy S.F. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 140 (2004) 813-816
21. Loven K., Stein L., Furst K., and Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24 (2002) 990-1000
22. Tanghetti E., and Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 6 (2007) 144-147
23. Fariba I., Ali A., Hossein S.A., Atefeh S., and Atarzadeh Behbahan S.A. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol 72 (2006) 346-349
24. Wolf Jr. J.E., Taylor J.R., Tschen E., and Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 40 (2001) 709-713
25. Rivers J.K., Arlette J., Shear N., Guenther L., Carey W., and Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 146 (2002) 94-100
26. Wellburn P, Dosik JS. Skin sensitization potential of PEP005 topical gel. Presented at: 65th Annual AAD Meeting; February 1-5, 2007; Washington, DC.